Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer

靶向补体增强复发性上皮性卵巢癌患者的抗肿瘤免疫并控制恶性积液

基本信息

  • 批准号:
    10689822
  • 负责人:
  • 金额:
    $ 64.57万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-24 至 2027-07-31
  • 项目状态:
    未结题

项目摘要

Abstract Epithelial ovarian cancer (OC) is the leading cause of death from gynecological malignancies in the United States. While OC is immunogenic and increased infiltration of cytotoxic T lymphocytes (CTL) correlates with longer survival, single agent checkpoint inhibitors are largely ineffective in the relapsed/refractory setting. Our long-term goal is to develop novel approaches to overcome obstacles to durable antitumor immunity to make immunotherapy more effective. Our results point to previously unrecognized mechanisms for mature neutrophils acquiring a suppressor phenotype within the tumor microenvironment (TME). Neutrophil suppressors inhibited stimulated proliferation of circulating naïve, central memory, and effector memory T cells, and of tumor-associated lymphocytes (TAL) from patients with newly diagnosed OC. Induction of the neutrophil suppressor phenotype required complement signaling and NADPH oxidase activation. A similar complement- dependent neutrophil suppressor phenotype was induced by ascites from patients with recurrent OC and from malignant effusions from patients with a number of metastatic cancers, underscoring the generalizability of our findings. These results in human samples and work by others in tumor-bearing mice support targeting complement to enhance anti-tumor immunity. We will evaluate APL-2, a peptide C3 inhibitor, in a randomized phase 2 clinical trial in patients with recurrent OC and persistent malignant effusions. APL-2 was safe and superior to eculizumab for paroxysmal nocturnal hemoglobinuria (PNH) and is FDA-approved for this indication; it’s use in cancer is novel. Following a safety lead-in, patients will be randomized to the following cohorts: (i) bevacizumab (anti-VEGF); (ii) APL-2 + pembrolizumab (anti-PD1); and (iii) APL-2 + pembrolizumab + bevacizumab. Specific Aim 1: To evaluate safety and control of malignant effusions as primary endpoints and progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), overall survival (OS), and quality of life (QoL) as secondary endpoints. Specific Aim 2: To determine the effects of APL-2-based therapy in modulation of immune responses in the TME. Patient samples (blood, effusion, tumor) will be collected at baseline and at pre-specified time points during the trial. We will test the extent that APL-2 will abrogate neutrophil suppressor activity and expand activated T cells in the TME. A combination of functional studies and transcriptional and mass cytometry profiling of circulating and ascites neutrophils and T cells will be performed. The impact of our proposal is to gain safety and preliminary efficacy data on APL-2- based regimens in recurrent OC with malignant effusions and a detailed understanding of how these regimens modulate the immune landscape in the TME. This research is expected to establish the foundation for larger randomized trials to definitively test the efficacy of C3 inhibition in enhancing cancer immunotherapy.
摘要 上皮性卵巢癌(OC)是美国妇科恶性肿瘤的主要死亡原因 各州。而OC是免疫原性的,细胞毒性T淋巴细胞(CTL)的浸润增加与 存活时间较长的单一药物检查点抑制剂在复发/难治环境中大多无效。我们的 长期目标是开发新的方法来克服持久抗肿瘤免疫的障碍,以使 免疫治疗更有效。我们的结果指出了以前未知的成熟机制 中性粒细胞在肿瘤微环境(TME)中获得抑制表型。中性粒细胞 抑制因子抑制循环中的幼稚T细胞、中央记忆T细胞和效应记忆T细胞的增殖。 以及新诊断OC患者的肿瘤相关淋巴细胞(TAL)。中性粒细胞的诱导 抑制表型需要补体信号和NADPH氧化酶的激活。类似的补充- 复发OC患者的腹水诱导依赖的中性粒细胞抑制表型 来自许多转移性癌症患者的恶性积液,强调了我们的 调查结果。这些在人类样本中的结果和其他人在荷瘤小鼠上的工作支持靶向 补充,增强抗肿瘤免疫力。我们将在一项随机的研究中评估APL-2,一种C3多肽抑制剂 复发性OC和持续性恶性积液患者的2期临床试验。APL-2是安全的 优于eculizumab治疗阵发性睡眠性血红蛋白尿(PNH),并得到FDA的批准 适应症;它在癌症中的应用是新颖的。在安全引导后,患者将被随机分为以下几组 队列:(I)贝伐单抗(抗血管内皮生长因子);(Ii)APL-2+pembrolizumab(抗PD1);以及(Iii)apl-2+pembrolizumab +贝伐单抗。具体目标1:评价恶性积液作为主要终点的安全性和可控性 和无进展生存率(PFS)、客观应答率(ORR)、疾病控制率(DCR)、总体 生存(OS)和生活质量(QOL)作为次要终点。具体目标2:确定 基于APL-2的治疗对TME免疫反应的调节作用。病人样本(血液、积液、肿瘤) 将在试验期间的基线和预先指定的时间点收集。我们将测试APL-2的程度 将消除中性粒细胞抑制活性,并扩大激活的T细胞在TME。一种组合 循环和腹水中性粒细胞和T细胞的功能研究及转录和质量细胞分析 将执行单元格。我们建议的影响是获得APL-2的安全性和初步疗效数据- 复发性OC伴恶性积液的基本治疗方案以及对这些方案的详细了解 调节TME中的免疫格局。这项研究有望为更大规模的 明确测试C3抑制在增强癌症免疫治疗中的有效性的随机试验。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brahm H Segal其他文献

Tratamiento de la Aspergilosis: Guías para la práctica clínica de la Sociedad de Enfermedades Infecciosas de los Estados Unidos de América (IDSA)
曲霉病治疗:美国联合感染协会 (IDSA) 临床实践指南
  • DOI:
    10.1086/590225
  • 发表时间:
    2008
  • 期刊:
  • 影响因子:
    11.8
  • 作者:
    Thomas J. Walsh;E. Anaissie;David W. Denning;Raoul Herbrecht;Dimitrios P. Kontoyiannis;Kieren A. Marr;Vicki A. Morrison;Brahm H Segal;William J. Steinbach;David A. Stevens;Jo;John R. Wingard;Thomas F. Patterson
  • 通讯作者:
    Thomas F. Patterson

Brahm H Segal的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brahm H Segal', 18)}}的其他基金

Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer
靶向补体增强复发性上皮性卵巢癌患者的抗肿瘤免疫并控制恶性积液
  • 批准号:
    10530911
  • 财政年份:
    2022
  • 资助金额:
    $ 64.57万
  • 项目类别:
Role of NADPH Oxidase in Regulating Inflammation
NADPH 氧化酶在调节炎症中的作用
  • 批准号:
    8213585
  • 财政年份:
    2009
  • 资助金额:
    $ 64.57万
  • 项目类别:
Role of NADPH Oxidase in Regulating Inflammation
NADPH 氧化酶在调节炎症中的作用
  • 批准号:
    7915353
  • 财政年份:
    2009
  • 资助金额:
    $ 64.57万
  • 项目类别:
Role of NADPH Oxidase in Regulating Inflammation
NADPH 氧化酶在调节炎症中的作用
  • 批准号:
    8012832
  • 财政年份:
    2009
  • 资助金额:
    $ 64.57万
  • 项目类别:
Role of NADPH Oxidase in Regulating Inflammation
NADPH 氧化酶在调节炎症中的作用
  • 批准号:
    8417735
  • 财政年份:
    2009
  • 资助金额:
    $ 64.57万
  • 项目类别:
Role of NADPH Oxidase in Regulating Inflammation
NADPH 氧化酶在调节炎症中的作用
  • 批准号:
    7662998
  • 财政年份:
    2009
  • 资助金额:
    $ 64.57万
  • 项目类别:

相似海外基金

Analyses of immune response and bacteria in cirrhotic ascites with Tm mapping method.
Tm 图谱法分析肝硬化腹水中的免疫反应和细菌。
  • 批准号:
    20K08305
  • 财政年份:
    2020
  • 资助金额:
    $ 64.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Randomized controlled trial to elucidate "would patients be weakened if ascites removed?"
随机对照试验阐明“如果腹水被清除,患者会变得虚弱吗?”
  • 批准号:
    20K16567
  • 财政年份:
    2020
  • 资助金额:
    $ 64.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of new immuno-cell therapy for the treatment of refractory malignant ascites and pleural effusion
开发新的免疫细胞疗法治疗难治性恶性腹水和胸腔积液
  • 批准号:
    19K09196
  • 财政年份:
    2019
  • 资助金额:
    $ 64.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Ascites proteomics reveal the mechanism of pancreatic cancer peritoneal dissemination
腹水蛋白质组学揭示胰腺癌腹膜播散机制
  • 批准号:
    19K18107
  • 财政年份:
    2019
  • 资助金额:
    $ 64.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
A Novel Therapy for gastrointestinal cancer targeting exosome in malignant ascites
一种针对恶性腹水中外泌体的胃肠癌新疗法
  • 批准号:
    18H02882
  • 财政年份:
    2018
  • 资助金额:
    $ 64.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Peritoneal metastasis Prediction by exosome in washing ascites for gastric cancer
胃癌洗腹水中外泌体预测腹膜转移
  • 批准号:
    18K16321
  • 财政年份:
    2018
  • 资助金额:
    $ 64.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Label-free microfluidic enrichment of cancer cells from noncancer cells in ascites fluid
无标记微流体从腹水中的非癌细胞中富集癌细胞
  • 批准号:
    9251748
  • 财政年份:
    2016
  • 资助金额:
    $ 64.57万
  • 项目类别:
Preparation of ascites purification device for cancerous ascites and establishment of portable continuous ascites purification perfusion method
癌性腹水腹水净化装置的研制及便携式连续腹水净化灌注方法的建立
  • 批准号:
    16K01425
  • 财政年份:
    2016
  • 资助金额:
    $ 64.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Label-free microfluidic enrichment of cancer cells from noncancer cells in ascites fluid
无标记微流体从腹水中的非癌细胞中富集癌细胞
  • 批准号:
    9036692
  • 财政年份:
    2016
  • 资助金额:
    $ 64.57万
  • 项目类别:
Identifying Factors in Malignant Ascites Facilitating Gastric Adenocarcinoma Peritoneal Metastasis
确定恶性腹水促进胃腺癌腹膜转移的因素
  • 批准号:
    349961
  • 财政年份:
    2015
  • 资助金额:
    $ 64.57万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了